Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/31/2002WO2002085399A1 Peptide-containing preparations
10/31/2002WO2002085396A1 Inhibition of jun kinase
10/31/2002WO2002085391A1 Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
10/31/2002WO2002085389A1 A non-lethal method for extracting crude hemocyanin from gastropod molluscs
10/31/2002WO2002085340A2 Oligonucleotide compositions and their use to induce differentiation of cells
10/31/2002WO2002085330A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/31/2002WO2002085311A2 Hcg formulation
10/31/2002WO2002085310A2 Antibiotics aa-896
10/31/2002WO2002085309A2 Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
10/31/2002WO2002085307A2 Glycopeptide antibiotics
10/31/2002WO2002085302A2 Methods of treating intestinal inflammation
10/31/2002WO2002085300A2 Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
10/31/2002WO2002085295A2 Methods and compositions for the modulation of biofilm formation
10/31/2002WO2002085289A2 Modulators of angiogenesis
10/31/2002WO2002085287A2 Minimal adenoviral vectors for immunization
10/31/2002WO2002085286A2 Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
10/31/2002WO2002085123A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002WO2002085117A1 Methods and compositions for preventing and treating septic shock and endotoxemia
10/31/2002WO2002085116A1 Sprr1a and axonal regeneration
10/31/2002WO2002085111A1 Flexible container system for storage of stabilized hemoglobin solutions
10/31/2002WO2002085093A2 Replikin peptides and uses thereof
10/31/2002WO2002071062A8 Diagnosis and treatment of inflammation and hyperactive immune conditions
10/31/2002WO2002070565A9 High-affinity antagonists of elr-cxc chemokines
10/31/2002WO2002068595A3 Mono-and diacylglycerol acyltransferases and methods of use thereof
10/31/2002WO2002068585A3 Tip39 polypeptides
10/31/2002WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002WO2002066650A3 Streptococcus pyogenes polypeptides and corresponding dna fragments
10/31/2002WO2002064161A9 Method and compositions for immunization with the pseudomonas v antigen
10/31/2002WO2002064022A3 Therapy for cerebral vasospasm
10/31/2002WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
10/31/2002WO2002060949A3 Glycoforms a fas ligand inhibitory protein analog
10/31/2002WO2002060947A3 Glycoforms a fas ligand inhibitory protein analog
10/31/2002WO2002060477A9 Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
10/31/2002WO2002058750A3 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same
10/31/2002WO2002055547A9 Sfrp and peptide motifs that interact with sfrp and methods of their use
10/31/2002WO2002055535A3 Antisense modulation of cytohesin-1 expression
10/31/2002WO2002052022A3 Selective cytotoxic fusion proteins
10/31/2002WO2002046219A3 Rho-gtpase activating proteins and methods related thereto
10/31/2002WO2002043750A3 Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
10/31/2002WO2002042489A9 Methods involving a t cell protein tyrosine phosphatase
10/31/2002WO2002042455A3 Modifier of organelle metalbolism
10/31/2002WO2002042412A3 Protease inhibitors and their pharmaceutical uses
10/31/2002WO2002040045A3 Microspheres of pancreatic enzymes with high stability
10/31/2002WO2002034913A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/31/2002WO2002033080A3 Regulation of human netrin binding membrane receptor unc5h-1
10/31/2002WO2002032959A3 Obesity-specific g protein coupled receptors
10/31/2002WO2002032283A3 Methods of and pharmaceutical compositions for improving implantation of embryos
10/31/2002WO2002028886A3 Caloxins their isolation and use
10/31/2002WO2002024912A3 Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
10/31/2002WO2002024885A3 Regulation of human g protein-coupled receptor
10/31/2002WO2002014499A3 Claudin polypeptides
10/31/2002WO2002012502A3 Anti-tnf antibodies, compositions, methods and uses
10/31/2002WO2002010392A3 Mammalian dna binding membrane-associated protein-encoding gene and uses
10/31/2002WO2002000262A3 Modulation of chromosome function by chromatin remodeling agents
10/31/2002WO2002000250A3 Hiv-1 vaccines and screening methods therefor
10/31/2002WO2001098343A3 Conserved diaphanous-related formin autoregulatory domain (dad)
10/31/2002WO2001093897A3 Angiostatin and endostatin binding proteins and methods of use
10/31/2002WO2001093896A3 A method of treatment of alzheimer's disease with a protein extractable from mammalian organs
10/31/2002WO2001093895A3 A method of treatment of huntington's chorea with a protein extractable from mammalian organs
10/31/2002WO2001093894A3 A method of treatment of parkinson's disease with a protein extractable from mammalian organs
10/31/2002WO2001088088A3 Novel nucleic acids and polypeptides
10/31/2002WO2001087348A3 Multifunctional nanodevice platform
10/31/2002WO2001075067A9 Novel nucleic acids and polypeptides
10/31/2002WO2001061356A9 Her-2 binding antagonists
10/31/2002WO2001059152A3 Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications
10/31/2002WO2001059065A9 Novel molecules of the card-related protein family and uses thereof
10/31/2002WO2001057251A9 Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
10/31/2002WO2001057072A3 Pharmacologically active antiviral peptides and methods of their use
10/31/2002WO2001053342A9 Chimeric prostate-homing peptides with pro-apoptotic activity
10/31/2002WO2001053335A9 Peptides with antibacterial activity
10/31/2002WO2001053331A9 Peptidomimetic modulators of cell adhesion
10/31/2002WO2001052746A9 Versatile hydrophilic dyes
10/31/2002WO2001051633A9 Compositions and methods for the therapy and diagnosis of prostate cancer
10/31/2002WO2001051632A9 Odorant receptor polypeptides and nucleic acids encoding same
10/31/2002WO2001044270A3 Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
10/31/2002WO2001036478A3 Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides
10/31/2002WO2001000198A3 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity
10/31/2002US20020162141 Selecting a target plant and transgene DNA molecule; constructing a plasmid; transforming an embryonic calli of target plant with tungsten particles coated with plasmid; culturing bombarded calli on a tissue culture medium
10/31/2002US20020162129 Prevention and treatment of alzheimer's disease
10/31/2002US20020162127 For use in diagnostic, therapeutic, and investigational procedures
10/31/2002US20020162126 Methods and compositions for RNA interference
10/31/2002US20020161399 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
10/31/2002US20020161234 Forming a diastereoselective epoxide from a chiral alpha-amino aldehyde
10/31/2002US20020161215 For use in assays designed to identify and characterize compounds which affect the function of such receptors, e.g., agonists and antagonists of NMDA receptors
10/31/2002US20020161210 Compositions, methods, and kits relating to resistin
10/31/2002US20020161209 For therapy of disease that is associated with an RNA molecule
10/31/2002US20020161204 Methods of detecting a liver disorder
10/31/2002US20020161203 Rattlesnake venom gland proteins
10/31/2002US20020161202 For modulating apoptosis in mammalian cells
10/31/2002US20020161200 For therapy
10/31/2002US20020161197 Defibrinating whole blood including red blood cells and a plasma component; filtering whole blood, whereby at least a portion of plasma is separated from red blood cells to form a red blood cell suspension, thereby purifying red blood cells
10/31/2002US20020161194 Cannine androgen receptor
10/31/2002US20020161193 Useful for the production of NMDA receptor subunit proteins, these nucleic acids are also useful as probes, to identify and isolate related human receptor subunits
10/31/2002US20020161191 Novel Imidazoline receptor homologs
10/31/2002US20020161189 Used in the antagonism and agonism of delta and mu opioid receptors
10/31/2002US20020161178 Novel DKR polypeptides
10/31/2002US20020161176 Providing solution comprising an echinocandin compound, an aldehyde impurity and solvent; concentrating by nanofiltration to form concentrate; adding derivatizing agent to react with aldehyde; adjusting pH, adding acid or metal salt; cooling
10/31/2002US20020161169 Hydrogel-forming system with hydrophobic and hydrophilic components
10/31/2002US20020161038 Inosine 5'-monophosphate dehydrogenase (IMPDH); prodrug having functional group -CO-N(-R)-COO-, a carrier, and an immunosuppressant, anticancer agent, antiviral agent, or anti-vascular hyperproliferation agent
10/31/2002US20020161032 Dosage form of a statin and microparticles of fenofibrate stabilized by a phospholipid surface active substrance; bioavailability unaffected by food intake
1 ... 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 ... 3163